Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-20
2005-09-20
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C435S069100, C435S069400
Reexamination Certificate
active
06946444
ABSTRACT:
Methods and pharmaceutical compositions useful for modulating lipoprotein levels in vivo. The invention stems from the discovery that activity of the Lipolysis Stimulated Receptor (LSR) can be inhibited or enhanced by exogenous agents, including polypeptides.
REFERENCES:
patent: 5270170 (1993-12-01), Schatz et al.
patent: 6579852 (2003-06-01), Fruebis et al.
patent: 6635431 (2003-10-01), Bihain et al.
patent: 2003/0100500 (2003-05-01), Fruebis et al.
patent: 2004/0067881 (2004-04-01), Fruebis et al.
patent: 2004/0077051 (2004-04-01), Bihain et al.
patent: WO 96/30400 (1996-10-01), None
patent: WO 96/34981 (1996-11-01), None
patent: WO 96/39429 (1996-12-01), None
patent: WO 97/27286 (1997-07-01), None
patent: WO 98/01257 (1998-01-01), None
patent: WO 98/20165 (1998-05-01), None
patent: WO 98/54311 (1998-12-01), None
patent: WO 99/04000 (1999-01-01), None
patent: WO 99/07736 (1999-02-01), None
patent: WO 99/10492 (1999-03-01), None
Austin, et al., “Hypertriglyceridemia as a Cardiovascular Risk Factor,”Am. J. Cardiol., 81:7B-12B, 1998.
Baldo, et al., “The Adlpsin-Acylation Stimulting Protein System and Regulation of Intracellular Triglyceride Synthesis,” J. Clin. Invest., 92:1543-1547 (1993).
Bartles, J.R., et al., “Biogenesis of the Rate Hepatocyte Plasma Membrane,”Methods Enzymol., 191: 825-841, 1990.
Bihain, B.E., et al., “Characterization and purification of the lipolysis-stimulated receptor,”Elsevier Science B.V., pp. 465-470, 1995.
Bihain, B.E., et al., “Free Fatty Aclids Activate a High-Affinity Saturable Pathway for Degradation of Low-Density Lipoproteins in Fibroblasts from a Subject Homozygous for Familial Hypercholesterolemia”Biochemistry, 31:4528-4638, 1992.
Brendel, V., et al., “Methods and algorithms for statistical analysis of protein sequences,”Proc. Natl. Acad. Sci. USA, 89:2002-2006, 1992.
Chen, .W.J., et al., “NPXY, a Sequence Often Found in Cytoplasmic Tails, Is Required for Coated Plt-mediated internalization of the Low Density Lipoprotein Receptor”,J. Biol. Chem., 265:3116-3123, 1990.
Cole-Strauss et al., “Correction of the Mutation Responsible for Sickle Cell Anemia by an RNA-DNA Oligonucleotide,”Science, 273:1386-1389, 1996.
Davis, C.G., et al., “The J.D. Mutation in Familial Hypercholesterolemia: Amino Acid Substitution in Cytoplasmic Domain Impedes Internalization of LDL Receptors,”Cell, 45:15-24, 1986.
Dietrich, J., et al., “CD3( Contains a Phosphoserine-Dependent Di-Leucine Motif Involved in Down-Regulation of the T Cell Receptor”, EMBO Journal 13:2156-2166 1994.
Everhart, J.E., “Weight Change and Obesity After Liver Transplantation: Incidence and Risk Factors,”Liver Transpl. Surg., 4:285-296, 1998.
Feeman, Jr., W.E., “Hypertriglyceridemia and Atherosclerosis,”Annals of Internal Medicine, vol. 128, No. 1, pp. 73-74, 1998.
Ghebrehiwet, et al., “Isolation, cDNA Cloning, and Overexpression of a 33-kD Cell Surface Glycoprotein that Binds to the Globular “Heads” of C1q,”J. Exp. Med., 179:1809-1821 (1994).
Goldstein, J.L., et al., “Familial Hypercholesterolemia,”The Metabolic and Molecular Bases of Inherited Disease, vol. II, 7thEdition (Scriver, C.R., et al., ed), McGraw-Hill, New York, pp. 1981-2030, 1995.
Goldstein, et al., “Hyperlipidemia in Coronary Heart Disease,”J. Clin. Invest., 52:1533-1543, 1973.
Gura, et al., “Obesity Sheds its Secrets”,Science, 275:751-753, Feb. 7, 1997.
Hayward, et al., “The cDNA Sequence of Human Endothelial Cell Multimerin,”J. Biol. Chem., 270:18246-18251, 1995.
Henrion, et al., “Structure, Sequence, and Chromosomal Location of the Gene for USF2 Transcription Factors in Mouse,” Genomics, 25:36-43 (1995).
Herz, J., et al., “Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor,” European Molecular Biology Laboratory, 7:4119-4127 (1988).
Honore, B., et al., “Cloning and expression of a cDNA covering the complete coding region of the P32 subunit of human pre-mRNA splicing factor SF2,”Gene, 134:283-287 (1993).
Hu, et al., “AdIpoQ is a Novel Adipose-specific Gene Dysregulated in Obesity,”J. Biol. Chem., 271:10697-10703 (1996).
Huettinger , M., et al., “Characteristics of Chylomicron Remnant Uptake into Rat Liver,”Clin. Biochem., 21:87-92 (1988).
Huto, et al., “AdipoQ is a Novel Adipose-specific Gene Dysregulated in Obesity,”Jr. of Biol. Chem., 271, 18:10697-10703 (1996).
Karpe, F., et al., “Clearance of lipoprotein remnant particles in adipose tissue and muscle in humans,”J. Lipid Res. 38:2335-2345 (1997).
Karpe, F., et al., “Magnitude of alimentary liperna is related to intima-media thickness of the common carotid artery in middle-aged men,”Elsevier Science Ireland, 141:307-314, 1998.
Khallou, et al., “Correction of Delayed Postprandial Plasma Lipid Response in Genetically Obese Mice by Injection of Recombinant Leptin,” Abstract from the 89thScientific Sessions, New Orleans, LA; Supplemental to Circulation, American Heart Assoc., vol. 94:8 (1996).
Krainer, A.R., et al., “Functional Expression of Cloned Human Splicing Factor SF2: Homology to RNA-Binding Proteins, U1 70K, and Orosophila Splicing Regulators,”Cell, 66:383-394, 1991.
Lee, M.G-S., et al., “Characterization of a cDNA Encoding a Cysteine-Rich Cell Surface Protein Located in the Flagellar Pocket of the ProtozoanTrypanosoma brucei,” Cell. Biol., 10:4506-4517 (1990).
Letoumour, F., et al., “A Novel Di-Leucine Motif and a Tyrosine-Based Motif Independently Mediate Lysosomal Targeting and Endocytosis of CD3 Chains,”Cell, 69:1143-1157 (1992).
Lewis, G.F., et al., “Postprandial Lipoprotein Metabolism in Normal and Obese Subjects: Comparison after the Vitamin A Fai-Loading Test,”Jr. of Clinic. Endo., 71:1041-1050, (1990).
Lin, et al., “Archaic Structure of the Gene Encoding Transcription Factor USF,”0Jr. of Bio. Chem., 269:23894-23903, (1994).
Liu, Q., et al., “Design of polydactyl zinc-finger proteins for unique addressing within complex genomes,”Proc. Natl. Acad. Sci. USA, 94:5525-5530, 1997.
Meeda, et al., “cDNA Cloning and Expression of a Novel Adipose Specific Collagen-like Factor, apM1 (Adipose Most Abundant Gene Transcript 1),”Biochem. and Biophys. Research Comm., 221:286-289, 1996.
Mahley, R.W., et al., “Type III Hyperlipoproteinemia (Dysbetalipoproleinemia): The Role of Apolipoprotein E in Normal and Abnormal Lipoprotein Metabolism,”The Molecular Basis of Inherited Disease, eds. Scriver, et al., McGraw Hill Inc., New York, pp. 1953-1980, 1995.
Mann, C.J., et al., “Mechanism of Activation and Functional Significance of the Lipolysis-Stimulated Receptor. Evidence for a Role as Chylomicron Remnant Receptor,”Biochemistry, 34:10421-14031 (1995).
Mann, et al., “ApoCIII inhibits the Binding of Triglyceride-Rich Lipoproteins to the Lipolysis Stimulated Receptor,” Abstract, (1996).
Massie, et al., “Inducible Overexpression of a Toxic Protein by an Adenovirus Vector with a Tetracycline-Regulstable Expression Cassette,”Journal of Virology, 72:2289-2296, 1998.
Montague, et al., “Congenital leptin deficiency is associated with severe early-onset obesity in humans,”Nature, 367:903-908, 1997.
Parra-Lopez, C.A., et al., “Presentation on Class II MHC Molecules of Endogenous Lysozyme Targeted to the Endocytic Pathway1”,J. Immunol., 158:2670-2679, 1997.
Pengus, G., et al., “Repression of transcriptional activity at a distance by the evolutionarily conserved KRAB domain present in a subfamily of zinc finger proteins,”Nucleic Acids Research, vol. 22, No. 15, 2908-2914 (1994).
Rajput-Williams, J., et al., “
Bihain Bernard
Bougueleret Lydie
Yen-Potin Frances
Carlson Karen Cochrane
Genset
Liu Samuel Wei
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Lipoprotein-regulating medicaments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipoprotein-regulating medicaments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoprotein-regulating medicaments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380369